Navigation Links
Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Date:1/21/2011

ry is an important advance in efforts by Genomic Health and its collaborators to develop a genomic test that could help physicians better target the use of oxaliplatin in colon cancer patients and highlights the company's commitment to conducting ongoing clinical research in this area.

About Oncotype DX® Colon Cancer Test

The Oncotype DX Colon Cancer test is the first multigene expression test commercially available that has been clinically validated to predict risk of recurrence in patients with stage II colon cancer.  For its colon cancer program, Genomic Health and its collaborators used the same rigorous clinical development strategy and standardized quantitative technology designed for the company's Oncotype DX Breast Cancer test.  National Surgical Adjuvant Breast and Bowel Project (NSABP) conducted three development studies and Cleveland Clinic conducted one development study, all of which were funded by Genomic Health, analyzing 761 genes from 1,851 patients with stage II colon cancer.  The final set of seven recurrence and five reference genes were then independently evaluated in 1,436 stage II colon cancer patients in the QUASAR validation study.  For more information about Oncotype DX for colon cancer, please visit www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.  Its lead product, the Oncotype DX® Breast Cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage ER+ breast cancer.  In addition to this widely adopted test, Genomic Health provides
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Everist Genomics Announces External Validation of OncoDefenderā„¢-CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients
2. BioInformatics, LLC New Market Report - Genomics Technologies
3. Transgenomic Reports Third Quarter Financial Results
4. Transgenomic Awarded $1,070,453 From U.S. Government Under the Patient Protection and Affordable Care Act
5. Transgenomic to Hold Third Quarter Financial Results Conference Call on November 15, 2010
6. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
7. Sirius Genomics Announces Issuance of U.S. Patent
8. AutoGenomics Receives FDA Clearance for its INFINITIĀ® CYP2C19 Assay
9. Genomic Health to Announce Third Quarter 2010 Financial Results and Host Conference Call on Monday, November 8, 2010
10. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
11. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 DuPont Pioneer and ... more than double the acreage contracted for Plenish® ... its soybean crush facility in Salisbury, Md. The ... will target several markets including foodservice and food ... performance. , For the 2015 growing season, Perdue ...
(Date:10/25/2014)... A new way to produce engineered ... current skin grafting technologies, it also speeds up the ... outlined in the October issue of STEM CELLS Translational ... injuries that result from severe burns and chronic wounds. ... regenerative elements. These wounds heal by contraction, with epithelization ...
(Date:10/25/2014)... Investor-Edge has initiated coverage on ... ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ), ... Pharmaceuticals Inc. (NASDAQ: PPHM ), and StemCells ... can be accessed at: http://investor-edge.com/register . ... on a positive note as the Dow Jones Industrial ...
(Date:10/22/2014)... and BOSTON , Oct. 22, ... a leading global specialty pharmaceutical company, and Rhythm, a ... an exclusive option to acquire Rhythm,s wholly owned subsidiary, ... peptide ghrelin agonist, for the treatment of diabetic gastroparesis ... has completed a successful Phase 2 trial of relamorelin ...
Breaking Biology Technology:DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... dollars, QUEBEC CITY, Nov. 12 /PRNewswire-FirstCall/ - ... a global biopharmaceutical company focused on,endocrine therapy and ... agreement to sell to Cowen Healthcare Royalty Partners, ... of Cetrotide(R) covered by,its license agreement with Merck ...
... Pasteur and Chumakov Institute Russian Academy Medical Sciences, ... ... National "Project Health", PARIS, November 12 ... Russia has,chosen inactivated polio vaccine (IPV) from Sanofi Pasteur for ...
... Standard & Poor,s will make the,following changes to the S&P 500 and S&P ... GGP) will be removed from the S&P 500 ... today,s close of trading General Growth Properties had a ... in the index., -- S&P MidCap 400 constituent Cephalon Inc. ...
Cached Biology Technology:AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 4Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 2Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 3Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 4Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 5Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 6Standard & Poor's Announces Changes to U.S. Indices 2Standard & Poor's Announces Changes to U.S. Indices 3
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
(Date:10/15/2014)... 2014 Sandata Technologies, LLC, an industry ... care, today announced it released a case study ... Visit Verification™ Solution (EVV™)  for Quality Care Services, ... company founded in 1996 and has five locations ... The study details the challenges facing Quality ...
(Date:10/15/2014)... pneumonia in female mice to an enzyme activated by ... more resistant to respiratory infections than males. Now, an ... to bacterial pneumonia in female mice is linked to ... show that this enzyme is ultimately activated by the ... team, lead by Professor Lester Kobzik at the Harvard ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... University of Alberta researchers discover that animals zig when ... told them. , In studying the spatial memory of ... to discover the birds contradicting prior research that showed ... reveal a different pattern. Previously, only animals that had ...
... study suggests that a suspect gene may increase susceptibility ... processing negative emotion. People with the depression-linked gene variant ... mood-regulating circuit. How well the circuit was connected accounted ... at the National Institute of Health's (NIH) National Institute ...
... billion neurons, and each has hundreds of connections with ... essential to understanding brain function, and the task is ... approach to mapping neuron connectivity published in PLoS Computational ... of Neuroscience at the University of Minnesota, the task ...
Cached Biology News:Chickadees can help humans get their bearings 2Depression gene may weaken mood-regulating circuit 2Depression gene may weaken mood-regulating circuit 3